NCI-2017-00226

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

This Phase 1 study is investigating a new drug called RGX-104, on its own and in combination therapy for patients with advanced solid cancers and lymphoma. The study aims to evaluate the safety and effectiveness of RGX-104 in treating these specific types of cancers. The study will also focus on expanding the investigation to select malignancies based on promising results.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT02922764

Clinical Trial Site: Columbia

To see all available clinical trials click here.